BetterLife Pharma Secures Funding for Treatment Development

BetterLife Pharma (TSE:BETR) has released an update.

BetterLife Pharma recently completed a non-brokered private placement, raising $530,000 by issuing 5.3 million units, with plans for an additional tranche aiming to raise $100,000. The company, specializing in treatments for mental disorders, is advancing two main compounds, BETR-001 and BETR-002, targeting neuro-psychiatric and neurological disorders. The CEO, Dr. Ahmad Doroudian, personally invested in the placement, which was conducted in accordance with Canadian securities laws.

For further insights into TSE:BETR stock, check out TipRanks’ Stock Analysis page.